Application of CRISPR/Cas9 System to Reverse ABC-Mediated Multidrug Resistance

被引：6

作者：

Wang, Wei ^{[1
]}

Liang, Ze ^{[1
]}

Ma, Pengfei ^{[1
]}

Zhao, Qi ^{[2
]}

Dai, Mengyuan ^{[3
]}

Zhu, Jie ^{[3
]}

Han, Xu ^{[1
]}

Xu, Hong ^{[4
]}

Chang, Qingyan ^{[5
]}

Zhen, Yuhong ^{[1
]}

机构：

[1] Dalian Med Univ, Coll Pharm, Dalian 116044, Peoples R China

[2] Dalian Med Univ, Affiliated Hosp 1, Dalian 116023, Peoples R China

[3] Dalian Med Univ, Affiliated Hosp 2, Dalian 116011, Peoples R China

[4] Dalian Med Univ, Coll Basic Med Sci, Dalian 116044, Peoples R China

[5] Dalian Med Univ, Pharm Dept, Dalian People Hosp 6, Dalian 116031, Peoples R China

来源：

BIOCONJUGATE CHEMISTRY | 2021年 / 32卷 / 01期

关键词：

EPITHELIAL OVARIAN-CANCER; P-GLYCOPROTEIN; IN-VIVO; EFFLUX TRANSPORTERS; CRISPR-CAS9; SYSTEM; DELIVERY; CELLS; RNA; PROTEIN; MDR1;

D O I：

10.1021/acs.bioconjchem.0c00627

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Multidrug resistance (MDR) is the main obstacle in cancer chemotherapy. ATP-binding cassette (ABC) transporters Drugs can transport a wide range of antitumor drugs out of cells, which is the most common reason in the development of resistance to drugs. Currently, various therapeutic strategies are used to reverse MDR, among which CRISPR/Cas9 gene editing technique is expected to be an effective way. Here, we reviewed the research progress of reversing ABC-mediated drug resistance by CRISPR/Cas9 system.

引用

页码：73 / 81

页数：9

共 79 条

[31] The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade [J].

Kathawala, Rishil J. ;

Gupta, Pranav ;

Ashby, Charles R., Jr. ;

Chen, Zhe-Sheng .

DRUG RESISTANCE UPDATES, 2015, 18 :1-17

[32] The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice [J].

Kemper, EM ;

Cleypool, C ;

Boogerd, W ;

Beijnen, JH ;

van Tellingen, O .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (02) :173-178

[33] Era of Genomic Medicine: A Narrative Review on CRISPR Technology as a Potential Therapeutic Tool for Human Diseases [J].

Kotagama, Odatha W. ;

Jayasinghe, Chanika D. ;

Abeysinghe, Thelma .

BIOMED RESEARCH INTERNATIONAL, 2019, 2019

[34]

Laustsen A, 2019, METHODS MOL BIOL, V1961, P127, DOI 10.1007/978-1-4939-9170-9_9

[35] Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer [J].

Lhomme, Catherine ;

Joly, Florence ;

Walker, Joan L. ;

Lissoni, Andrea A. ;

Nicoletto, Maria O. ;

Manikhas, Gregory M. ;

Baekelandt, Mark M. O. ;

Gordon, Alan N. ;

Fracasso, Paula M. ;

Mietlowski, William L. ;

Jones, Gary J. ;

Dugan, Margaret H. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) :2674-2682

[36] Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities [J].

Li, Ling ;

Hu, Shuo ;

Chen, Xiaoyuan .

BIOMATERIALS, 2018, 171 :207-218

[37] Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors [J].

Li, Ling ;

He, Zhi-Yao ;

Wei, Xia-Wei ;

Gao, Guang-Ping ;

Wei, Yu-Quan .

HUMAN GENE THERAPY, 2015, 26 (07) :452-462

[38] Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance [J].

Li, Shuaizhang ;

Zhang, Wen ;

Yin, Xuejiao ;

Xing, Shilai ;

Xie, Heidi Qunhui ;

Cao, Zhengyu ;

Zhao, Bin .

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2015, 15 (04) :423-432

[39] Development and Characterization of MDR1 (Mdr1a/b) CRISPR/Cas9 Knockout Rat Model [J].

Liang, Chenmeizi ;

Zhao, Junfang ;

Lu, Jian ;

Zhang, Yuanjin ;

Ma, Xinrun ;

Shang, Xuyang ;

Li, Yongmei ;

Ma, Xueyun ;

Liu, Mingyao ;

Wang, Xin .

DRUG METABOLISM AND DISPOSITION, 2019, 47 (02) :71-79

[40] Delivering CRISPR: a review of the challenges and approaches [J].

Lino, Christopher A. ;

Harper, Jason C. ;

Carney, James P. ;

Timlin, Jerilyn A. .

DRUG DELIVERY, 2018, 25 (01) :1234-1257

← 1 2 3 4 5 6 7 8 →